NEW YORK (GenomeWeb News) – Nanosphere said today that its second quarter revenues jumped 38 percent year over year, with the rise being driven by sales of its Verigene Gram-Positive Blood Culture Test.

Nanosphere also lowered its revenue guidance for the year as well as its expectations for instrument placements. In response, its shares plummeted around 32 percent to $2.00 in Wednesday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.